The Syrian hamster model of hantavirus pulmonary syndrome

David Safronetz, Hideki Ebihara, Heinz Feldmann, Jay W. Hooper

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

Hantavirus pulmonary syndrome (HPS) is a relatively rare, but frequently fatal disease associated with New World hantaviruses, most commonly Sin Nombre and Andes viruses in North and South America, respectively. It is characterized by fever and the sudden, rapid onset of severe respiratory distress and cardiogenic shock, which can be fatal in up to 50% of cases. Currently there are no approved antiviral therapies or vaccines for the treatment or prevention of HPS. A major obstacle in the development of effective medical countermeasures against highly pathogenic agents like the hantaviruses is recapitulating the human disease as closely as possible in an appropriate and reliable animal model. To date, the only animal model that resembles HPS in humans is the Syrian hamster model. Following infection with Andes virus, hamsters develop HPS-like disease which faithfully mimics the human condition with respect to incubation period and pathophysiology of disease. Perhaps most importantly, the sudden and rapid onset of severe respiratory distress observed in humans also occurs in hamsters. The last several years has seen an increase in studies utilizing the Andes virus hamster model which have provided unique insight into HPS pathogenesis as well as potential therapeutic and vaccine strategies to treat and prevent HPS. The purpose of this article is to review the current understanding of HPS disease progression in Syrian hamsters and discuss the suitability of utilizing this model to evaluate potential medical countermeasures against HPS.

Original languageEnglish (US)
Pages (from-to)282-292
Number of pages11
JournalAntiviral Research
Volume95
Issue number3
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Hantavirus Pulmonary Syndrome
Mesocricetus
Hantavirus
Cricetinae
Sin Nombre virus
Animal Models
Active Immunotherapy
Cardiogenic Shock
South America
North America
Lung Diseases
Antiviral Agents
Disease Progression
Fever
Vaccines

Keywords

  • Andes virus
  • Animal model
  • Bunyavirus
  • Hamster
  • Hantavirus pulmonary syndrome

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

The Syrian hamster model of hantavirus pulmonary syndrome. / Safronetz, David; Ebihara, Hideki; Feldmann, Heinz; Hooper, Jay W.

In: Antiviral Research, Vol. 95, No. 3, 01.09.2012, p. 282-292.

Research output: Contribution to journalReview article

Safronetz, David ; Ebihara, Hideki ; Feldmann, Heinz ; Hooper, Jay W. / The Syrian hamster model of hantavirus pulmonary syndrome. In: Antiviral Research. 2012 ; Vol. 95, No. 3. pp. 282-292.
@article{16dc08e804de47c99929f8cb04e30a57,
title = "The Syrian hamster model of hantavirus pulmonary syndrome",
abstract = "Hantavirus pulmonary syndrome (HPS) is a relatively rare, but frequently fatal disease associated with New World hantaviruses, most commonly Sin Nombre and Andes viruses in North and South America, respectively. It is characterized by fever and the sudden, rapid onset of severe respiratory distress and cardiogenic shock, which can be fatal in up to 50{\%} of cases. Currently there are no approved antiviral therapies or vaccines for the treatment or prevention of HPS. A major obstacle in the development of effective medical countermeasures against highly pathogenic agents like the hantaviruses is recapitulating the human disease as closely as possible in an appropriate and reliable animal model. To date, the only animal model that resembles HPS in humans is the Syrian hamster model. Following infection with Andes virus, hamsters develop HPS-like disease which faithfully mimics the human condition with respect to incubation period and pathophysiology of disease. Perhaps most importantly, the sudden and rapid onset of severe respiratory distress observed in humans also occurs in hamsters. The last several years has seen an increase in studies utilizing the Andes virus hamster model which have provided unique insight into HPS pathogenesis as well as potential therapeutic and vaccine strategies to treat and prevent HPS. The purpose of this article is to review the current understanding of HPS disease progression in Syrian hamsters and discuss the suitability of utilizing this model to evaluate potential medical countermeasures against HPS.",
keywords = "Andes virus, Animal model, Bunyavirus, Hamster, Hantavirus pulmonary syndrome",
author = "David Safronetz and Hideki Ebihara and Heinz Feldmann and Hooper, {Jay W.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.antiviral.2012.06.002",
language = "English (US)",
volume = "95",
pages = "282--292",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - The Syrian hamster model of hantavirus pulmonary syndrome

AU - Safronetz, David

AU - Ebihara, Hideki

AU - Feldmann, Heinz

AU - Hooper, Jay W.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Hantavirus pulmonary syndrome (HPS) is a relatively rare, but frequently fatal disease associated with New World hantaviruses, most commonly Sin Nombre and Andes viruses in North and South America, respectively. It is characterized by fever and the sudden, rapid onset of severe respiratory distress and cardiogenic shock, which can be fatal in up to 50% of cases. Currently there are no approved antiviral therapies or vaccines for the treatment or prevention of HPS. A major obstacle in the development of effective medical countermeasures against highly pathogenic agents like the hantaviruses is recapitulating the human disease as closely as possible in an appropriate and reliable animal model. To date, the only animal model that resembles HPS in humans is the Syrian hamster model. Following infection with Andes virus, hamsters develop HPS-like disease which faithfully mimics the human condition with respect to incubation period and pathophysiology of disease. Perhaps most importantly, the sudden and rapid onset of severe respiratory distress observed in humans also occurs in hamsters. The last several years has seen an increase in studies utilizing the Andes virus hamster model which have provided unique insight into HPS pathogenesis as well as potential therapeutic and vaccine strategies to treat and prevent HPS. The purpose of this article is to review the current understanding of HPS disease progression in Syrian hamsters and discuss the suitability of utilizing this model to evaluate potential medical countermeasures against HPS.

AB - Hantavirus pulmonary syndrome (HPS) is a relatively rare, but frequently fatal disease associated with New World hantaviruses, most commonly Sin Nombre and Andes viruses in North and South America, respectively. It is characterized by fever and the sudden, rapid onset of severe respiratory distress and cardiogenic shock, which can be fatal in up to 50% of cases. Currently there are no approved antiviral therapies or vaccines for the treatment or prevention of HPS. A major obstacle in the development of effective medical countermeasures against highly pathogenic agents like the hantaviruses is recapitulating the human disease as closely as possible in an appropriate and reliable animal model. To date, the only animal model that resembles HPS in humans is the Syrian hamster model. Following infection with Andes virus, hamsters develop HPS-like disease which faithfully mimics the human condition with respect to incubation period and pathophysiology of disease. Perhaps most importantly, the sudden and rapid onset of severe respiratory distress observed in humans also occurs in hamsters. The last several years has seen an increase in studies utilizing the Andes virus hamster model which have provided unique insight into HPS pathogenesis as well as potential therapeutic and vaccine strategies to treat and prevent HPS. The purpose of this article is to review the current understanding of HPS disease progression in Syrian hamsters and discuss the suitability of utilizing this model to evaluate potential medical countermeasures against HPS.

KW - Andes virus

KW - Animal model

KW - Bunyavirus

KW - Hamster

KW - Hantavirus pulmonary syndrome

UR - http://www.scopus.com/inward/record.url?scp=84865299409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865299409&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2012.06.002

DO - 10.1016/j.antiviral.2012.06.002

M3 - Review article

VL - 95

SP - 282

EP - 292

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 3

ER -